These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 12169712)

  • 61. When will the U.S. flinch at cancer drug prices?
    Vanchieri C
    J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
    [No Abstract]   [Full Text] [Related]  

  • 62. Patent nonsense: evidence tells of an industry out of social control.
    Mintzberg H
    CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
    [No Abstract]   [Full Text] [Related]  

  • 63. Regulating vaccines: can health-economics tools be used profitably?
    Dhanasiri SK; Puliyel JM
    Indian Pediatr; 2007 Jan; 44(1):11-4. PubMed ID: 17277425
    [No Abstract]   [Full Text] [Related]  

  • 64. Exploring the rise in American pharmaceutical prices.
    Marwaha A
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(2):11-5. PubMed ID: 12099112
    [No Abstract]   [Full Text] [Related]  

  • 65. National vaccine injury compensation program: calculation of average cost of a health insurance policy. Final rule.
    Health Resources and Services Administration (HRSA), HHS
    Fed Regist; 2007 Jul; 72(128):36610-2. PubMed ID: 17674490
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM
    Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Drug, DME firms expect to get benefits from GATT.
    Gardner J
    Mod Healthc; 1994 Dec; 24(49):8. PubMed ID: 10138663
    [No Abstract]   [Full Text] [Related]  

  • 68. Vaccine finance resources for physicians.
    Sobczyk E
    Pediatrics; 2009 Dec; 124 Suppl 5():S573-6. PubMed ID: 19948594
    [No Abstract]   [Full Text] [Related]  

  • 69. Pharmacoeconomics comes of age?
    Walley T; Breckenridge A
    Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Strategies for paying for health services in developing countries.
    de Ferranti D
    World Health Stat Q; 1984; 37(4):428-50. PubMed ID: 6441359
    [No Abstract]   [Full Text] [Related]  

  • 71. Improving access to vaccines through tiered pricing.
    Berkley S
    Lancet; 2014 Jun; 383(9936):2265-7. PubMed ID: 24636625
    [No Abstract]   [Full Text] [Related]  

  • 72. Licensing IP to ensure accessibility to vaccines and other immunisation-related products.
    Mehta JM
    Vaccine; 2001 Feb; 19(13-14):1581-7; discussion 1592-3. PubMed ID: 11166878
    [No Abstract]   [Full Text] [Related]  

  • 73. Potential stifling effects of pharmaco-economics and regulatory policies.
    Data JL
    Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
    [No Abstract]   [Full Text] [Related]  

  • 74. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
    Alifrangis C; Krell J; Stebbing J
    Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
    [No Abstract]   [Full Text] [Related]  

  • 75. 500m dollars investment in poor countries' health systems will boost vaccination.
    Zarocostas J
    BMJ; 2007 Feb; 334(7587):225. PubMed ID: 17272541
    [No Abstract]   [Full Text] [Related]  

  • 76. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
    Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H
    Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Health Impact Fund.
    Norris J
    Lancet; 2010 Mar; 375(9718):893. PubMed ID: 20226985
    [No Abstract]   [Full Text] [Related]  

  • 78. Immunization financing: key area for American Academy of Pediatrics advocacy.
    Tayloe DT
    Pediatrics; 2009 Dec; 124 Suppl 5():S455-6. PubMed ID: 19948575
    [No Abstract]   [Full Text] [Related]  

  • 79. Why Europe leads U.S. in interventional devices.
    Marchant J
    Diagn Imaging (San Franc); 1997 Nov; 19(11):73-7. PubMed ID: 10176119
    [No Abstract]   [Full Text] [Related]  

  • 80. The health impact fund.
    Banerjee A; Pogge T; Hollis A
    Lancet; 2010 May; 375(9727):1693. PubMed ID: 20472169
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.